CN103857689A - Osw-1类似物和缀合物，及其用途 - Google Patents

Osw-1类似物和缀合物，及其用途 Download PDF

Info

Publication number
CN103857689A
CN103857689A CN201280035918.9A CN201280035918A CN103857689A CN 103857689 A CN103857689 A CN 103857689A CN 201280035918 A CN201280035918 A CN 201280035918A CN 103857689 A CN103857689 A CN 103857689A
Authority
CN
China
Prior art keywords
compound
aforementioned compounds
osbp1
hydrogen
instances
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201280035918.9A
Other languages
English (en)
Chinese (zh)
Inventor
M.D.沙伊尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Harvard University
Original Assignee
Harvard University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard University filed Critical Harvard University
Publication of CN103857689A publication Critical patent/CN103857689A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J17/005—Glycosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/24—Condensed ring systems having three or more rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201280035918.9A 2011-05-19 2012-05-18 Osw-1类似物和缀合物，及其用途 Pending CN103857689A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161488023P 2011-05-19 2011-05-19
US61/488,023 2011-05-19
PCT/US2012/038562 WO2012159027A2 (en) 2011-05-19 2012-05-18 Osw-1 analogs and conjugates, and uses thereof

Publications (1)

Publication Number Publication Date
CN103857689A true CN103857689A (zh) 2014-06-11

Family

ID=47177654

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280035918.9A Pending CN103857689A (zh) 2011-05-19 2012-05-18 Osw-1类似物和缀合物，及其用途

Country Status (5)

Country Link
US (1) US9790253B2 (https=)
EP (1) EP2710024A4 (https=)
JP (1) JP2014515354A (https=)
CN (1) CN103857689A (https=)
WO (1) WO2012159027A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105056236A (zh) * 2015-08-13 2015-11-18 暨南大学 Orp4l在制备治疗急性髓性白血病产品中的应用

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
WO2020160156A2 (en) 2019-01-30 2020-08-06 Immutics, Inc. Anti-gal3 antibodies and uses thereof
CN111159770B (zh) * 2019-12-31 2022-12-13 医渡云（北京）技术有限公司 文本数据脱敏方法、装置、介质及电子设备
EP4157338A4 (en) 2020-05-26 2024-11-13 TrueBinding, Inc. METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING
FR3125047B1 (fr) * 2021-07-06 2024-03-15 Centre Nat Rech Scient Composé de type 7a,8,9,10,11,11a-hexahydro-1H,7H-pyrano[2,3-c]xanthene, leur procédé de préparation, leurs intermédiaires et leurs applications thérapeutiques.

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010068877A2 (en) * 2008-12-11 2010-06-17 President And Fellows Of Harvard College Compounds that bind oxysterol binding proteins, and methods of use thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4318924A1 (de) 1993-06-03 1994-12-08 Schering Ag Cephalostatin-Analoga
JPH0948794A (ja) 1995-06-02 1997-02-18 Yutaka Sashita ステロイド配糖体及びこれを有効成分とする医薬
US7321050B2 (en) 1999-12-06 2008-01-22 Welichem Biotech Inc. Anti-inflammatory and psoriasis treatment and protein kinase inhibition by hydroxy stilbenes and novel stilbene derivatives and analogues
US6753414B2 (en) 2001-08-07 2004-06-22 University Of Iowa Research Foundation, Inc. Process for preparing saponin compounds
DK1545613T3 (da) 2002-07-31 2011-11-14 Seattle Genetics Inc Auristatinkonjugater og deres anvendelse til behandling af cancer, en autoimmun sygdom eller en infektiøs sygdom
US20050004044A1 (en) 2003-04-07 2005-01-06 Board Of Regents Use of orsaponin [3beta, 16beta, 17 alpha-trihydroxycholost-5-en-22-one 16-0-(2-0-4-methoxybenzoyl-beta-D-xylopyranosyl)-(1->3)-(2-0-acetyl-alpha-L-arabinopyranoside)] or OSW-1 and its derivatives for cancer therapeutics
EP2478912B1 (en) 2003-11-06 2016-08-31 Seattle Genetics, Inc. Auristatin conjugates with anti-HER2 or anti-CD22 antibodies and their use in therapy
US7358377B2 (en) 2004-03-29 2008-04-15 University Of Iowa Research Foundation Schweinfurthin analogues
CN1844138A (zh) 2006-05-12 2006-10-11 中国科学院上海有机化学研究所 一种合成虎眼万年青皂甙的脱除保护基的方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010068877A2 (en) * 2008-12-11 2010-06-17 President And Fellows Of Harvard College Compounds that bind oxysterol binding proteins, and methods of use thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MINPEI KURODA ET AL.，: "Cytotoxic Cholestane Glycosides from the Bulbs of Ornithogalum saundersiae", 《J. NAT. PROD.》, vol. 64, no. 1, 23 November 2000 (2000-11-23), pages 89 - 4 *
谢明霞 等: "虎眼万年青皂苷及其衍生物研究进展", 《中国药房》, vol. 20, no. 12, 30 April 2009 (2009-04-30), pages 950 - 952 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105056236A (zh) * 2015-08-13 2015-11-18 暨南大学 Orp4l在制备治疗急性髓性白血病产品中的应用

Also Published As

Publication number Publication date
EP2710024A2 (en) 2014-03-26
WO2012159027A3 (en) 2013-03-28
JP2014515354A (ja) 2014-06-30
WO2012159027A2 (en) 2012-11-22
US9790253B2 (en) 2017-10-17
US20140135279A1 (en) 2014-05-15
EP2710024A4 (en) 2015-04-29

Similar Documents

Publication Publication Date Title
JP6059723B2 (ja) ４−（８−メトキシ−１−（（１−メトキシプロパン−２−イル）−２−（テトラヒドロ−２Ｈ−ピラン−４−イル）−１Ｈ−イミダゾ［４，５−ｃ］キノリン−７−イル）−３，５−ジメチルイソオキサゾールおよびブロモドメイン阻害剤としてのその使用
CN107406416B (zh) 新型取代的吲唑、其制备方法、包含其的药物制剂及其用于制备药物的用途
KR102322794B1 (ko) 핵수송 조절인자 및 이의 용도
CN103857689A (zh) Osw-1类似物和缀合物，及其用途
AU2021269433A1 (en) Glucocorticoid receptor agonist and immunoconjugates thereof
JP6300730B2 (ja) ベツリンの誘導体
WO2012013816A1 (en) Compounds and methods for treating neoplasia
JP6821701B2 (ja) Ｎ−［２−（３−ヒドロキシ−３−メチルブチル）−６−（２−ヒドロキシプロパン−２−イル）−２ｈ−インダゾール−５−イル］−６−（トリフルオロメチル）ピリジン−２−カルボキサミドの結晶形態
US20200000822A1 (en) Methods of treatment for cancer, sterol homeostasis, and neurological diseases
CN101928288A (zh) 结合hsp90的小分子组合物
JP2019196390A (ja) 非アポトーシス性の制御された細胞死の阻害剤としてのスピロキノキサリン誘導体
JP7078405B2 (ja) カリケアマイシン誘導体およびその抗体薬物コンジュゲート
JP5902206B2 (ja) 脾臓チロシンキナーゼ（Ｓｙｋ）の阻害薬として有用なピリジニル及びピラジニルメチルオキシアリール誘導体
CN115715201A (zh) 葡萄糖雷公藤甲素缀合物及其用途
WO2021150885A1 (en) Cannabinoid derivatives
Wang et al. A novel evodiamine amino derivative as a PI3K/AKT signaling pathway modulator that induces apoptosis in small cell lung cancer cells
US11773096B2 (en) Small-molecule PI5P4K alpha/beta inhibitors and methods of treatment using same
ES2312965T3 (es) Sulfamatos de d-homoestra-1,3,5(10)-trien-3-il-2-sustituidos con efectos antitumoral.
US20230151021A1 (en) Compounds and Compositions for Treating Hematologic Malignancies
US20110319352A1 (en) Compounds That Bind Oxysterol Binding Proteins, and Methods of Use Thereof
Miao et al. Discovery of SZJK-0421: A Novel Potent, Low Toxicity, Selective Second Generation of CRM1 Inhibitor for the Treatment of Both Hematological and Solid Tumors
NL2037477B1 (en) Anticancer Compounds
CA3107823A1 (en) Methods of activating microglial cells
TWI748936B (zh) 新穎化合物
HK40093529A (zh) 5α-羟基-6β-[2-(1H-咪唑-4-基)乙基氨基]胆甾烷-3β-醇的前药及包含其的用於癌症治疗的药物组合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20140611